NIO Webinar: Alternative Funding for Drug Development through NIH Blueprint for Neurotherapeutics

PLEASE NOTE CORRECT WEBINAR LINK AND CALL IN INFORMATION HERE (UPDATED MONDAY, JULY 9):

Online:

https://webmeeting.nih.gov/r44092278/
Conference Number(s): 1-888-450-5996
Participant Code: 761442

Audio Only:

Conference Number(s): 1-888-450-5996
Participant Code: 761442

Please join the Neurotechnology Industry Organization (NIO) and the National Institute of Neurological Disorders & Stroke (NINDS), Office of Translational Research for a webinar on the NIH Blueprint Neurotherapeutics Program to be held Tuesday July 10th, 2012 at 1:00 pm EST. In this 45 minute webinar the Program Director of Blueprint Neurotherapeutics, Dr. Rebecca Farkas, will describe the program and answer your questions.

In the webinar you will learn how to:

Utilize the NINDS virtual pharma capability
Receive valuable services during a 5 year program to reach early proof of concept studies in humans
Retain all intellectual property rights generated
Have your questions answered by NINDS experts

Blueprint Neurotherapeutics is a pilot NIH program focused on small molecule drug discovery. It provides full drug discovery and development capabilities to biotechnology companies and academics, to take drug projects from the medicinal chemistry to human proof of concept. The NIH has set up seasoned teams of industry researcher-consultants who work collaboratively with principal investigators in a "virtual pharma" model.

Biotechnology companies in the United States and around the world may apply, as well as academics. Inventions arising in the partnership are assigned to the PI's institution.
The deadline for submission to the final round of applications, to become a Blueprint Neurotherapeutics program awardee, is October 8th, 2012. There are 11 drug projects in the program so far, and the goal is to award up to an additional 9 projects.